Navigation Links
Discovery Labs Reports Third Quarter 2013 Financial Results
Date:11/12/2013

quarter ended September 30, 2013 were $10.1 million compared to $9.9 million for the same period in 2012.  The operating loss for the quarter ended September 30, 2013 includes a $1.3 million investment to prepare for the AEROSURF phase 2 clinical trials.As of September 30, 2013, the Company had cash and cash equivalents of $21.2 million. On November 5, 2013, the Company completed a public offering of 25 million shares of common stock at a price of $2.00 per share, resulting in net proceeds to the Company (after underwriting discount and anticipated expenses) of approximately $46.8 million.  The Company also granted the underwriters a 30-day option to purchase up to an additional 3.75 million shares of common stock at an offering price of $2.00 to cover over-allotments, if any.  On November 8, 2013, the underwriter notified the Company that it has exercised its over-allotment option to purchase 3.75 million additional shares of common stock.  The exercise of the option is expected to close on or about November 14, 2013 and result in net proceeds (after underwriting discount) of approximately $7.1 million.

Additionally, with the commercial introduction of SURFAXIN, the Company became eligible under its  $30 million secured loan facility with Deerfield to receive the final $20 million advance, which is expected on or about December 3, 2013.  The initial $10 million was advanced in February 2013 upon execution of the facility agreement.  In connection with the $20 million advance, Deerfield will receive a transaction fee equal to 1.5% of the advance, and warrants to purchase approximately 4.7 million shares of common stock at an exercise price of $2.81 per share.

In October 2013, the Company initiated an offering under its at-the-market (ATM) Program with Stifel, Nicolaus & Company, Incorporated and issued 713,920 shares of common stock at an average price per share of $2.75, resulting in net proceeds (after a 3%
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
2. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
3. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
4. Discovery Labs Announces Completion of $50 Million Public Offering
5. Discovery Labs Prices $50 Million Public Offering of Common Stock
6. Discovery Labs Announces Proposed Public Offering of Common Stock
7. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
8. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
9. Drug Discovery Using Natural Products - Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents, New Life Science Webinar Hosted by Xtalks
10. Global Biosimulation Technology Market (For Drug Discovery & Development) (2012 - 2017)
11. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... , April 23, 2015 /CNW/ - A new and ... award from North America,s ... Comparison won Silver in the "Sustainability, service" category ... The Brandcheck "Competitor Comparison" is a service that ... American and Global peers. This benchmarking process shows ...
(Date:4/23/2015)... California (PRWEB) April 23, 2015 ... diagnostics refer to a series of genetic tests ... cystic fibrosis, Lou Gehrig's disease, Huntington's disease, and ... examining the gene composition and interaction in diseased ... disease as well as the response to treatment, ...
(Date:4/23/2015)... April 23, 2015 Proove ... Personalized Medicine, is excited to announce the launch ... . This profile assesses 62 genetic variations to ... information for commonly prescribed non-opioid pain medications, namely ... Neurontin), alprazolam (brand name Xanax) and acetaminophen (brand ...
(Date:4/23/2015)... Delpor, Inc. (Delpor), a biotechnology company focused ... Patent and Trademark Office has issued 2 new patents ... US Pat. No. 8,986,727 was issued on March 24, ... for the sustained release of therapeutic agents. The ... (zero-order) release of large and small molecules for several ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... , ANNAPOLIS, Md. , Feb. 1 ... biodefense company developing medical countermeasures against biological and chemical ... Paper in response to the Broad Agency Announcement (Solicitation ... Development Authority (BARDA) for the Advanced Research and ...
... , Feb. 1 Telik, Inc. (Nasdaq: TELK ) ... 12th Annual BIO CEO & Investor Conference in New York City ... time ( 12:00 p.m. Pacific time ).  A live and archived ... www.telik.com . , Telik, Inc. of Palo Alto, CA , is ...
... , SAN FRANCISCO , Feb. 1 ... a placement agent in GenVec, Inc.,s (Nasdaq: GNVC ) ... stock, and warrants to purchase 4.2 million shares of common stock, ... http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with the Merriman team ...
Cached Biology Technology:PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 2PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 3PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Cancer Research Center have, for the first time, induced ... achievement, the first demonstration of "hibernation on demand" in ... treat cancer and prevent injury and death from insufficient ... in essence, temporarily converting mice from warm-blooded to cold-blooded ...
... that are invisible by ordinary means of detection, according ... of Medicine in St. Louis. , The researchers demonstrated ... from the surrounding tissue by direct MRI scan--could be ... minutes after the mice were injected with the nanoparticles. ...
... the March issue of the journal Cancer Cell describes a ... to a new avenue for targeted cancer therapy. The compound, ... mouse model system and has low toxicity. The results of ... in phase I clinical trials. , Plk1 is a molecule ...
Cached Biology News:Buying Time Through Hibernation on Demand 2Buying Time Through Hibernation on Demand 3Buying Time Through Hibernation on Demand 4Buying Time Through Hibernation on Demand 5Nanoparticles offer new hope for detection and treatment 2Nanoparticles offer new hope for detection and treatment 3New drug shows promise as powerful anticancer agent 2